What is the cheapest emergency glucose replacement option between Gvoke (glucagon), Zegaloge (dasiglucagon) and Baqsimi (nasal glucagon)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cheapest Emergency Glucose Replacement Option Among Gvoke, Zegaloge, and Baqsimi

Based on the most recent cost data from 2023, traditional injectable glucagon powder with diluent for reconstitution is the cheapest emergency glucose replacement option at $249 NADAC, followed by nasal glucagon (Baqsimi) at $270 NADAC, and prefilled pen/syringe glucagon (Gvoke) at $285 NADAC, while dasiglucagon (Zegaloge) has no available NADAC data but has the highest AWP at $371. 1

Cost Comparison

  • According to the American Diabetes Association's 2024 Standards of Care, the National Average Drug Acquisition Cost (NADAC) for emergency glucose replacement options are:

    • Traditional injectable glucagon powder with diluent: $249 ($225-$273) 1
    • Nasal glucagon (Baqsimi): $270 1
    • Prefilled pen/syringe glucagon (Gvoke): $285 1
    • Dasiglucagon (Zegaloge): No NADAC data available, but AWP is $371 1
  • When considering Average Wholesale Price (AWP), the cost ranking remains the same:

    • Traditional injectable glucagon powder: $266 ($194-$369) 1
    • Nasal glucagon (Baqsimi): $337 1
    • Prefilled pen/syringe glucagon (Gvoke): $368 1
    • Dasiglucagon (Zegaloge): $371 1

Clinical Considerations Beyond Cost

  • While traditional injectable glucagon is the cheapest option, it requires reconstitution before use, which can be challenging during an emergency situation 1

  • Ready-to-use formulations like nasal glucagon (Baqsimi) and prefilled pens (Gvoke, Zegaloge) are preferred due to their ease of administration, resulting in more rapid correction of hypoglycemia 1

  • Studies show that caregivers and non-medical personnel can administer nasal glucagon within 1 minute compared to 1.3-5 minutes with intramuscular glucagon, which may be critical during severe hypoglycemic events 2, 3

  • In simulation studies, the success rate for administration was significantly higher with nasal glucagon (89.5%) compared to injectable glucagon (26.3%) 3

Insurance Coverage Considerations

  • Health insurance providers may prefer only select glucagon products, so it's important to check individual insurance coverage and prescribe formulary products whenever possible 1

  • Out-of-pocket costs will vary depending on insurance coverage, formulary tier placement, and whether the patient qualifies for assistance programs 4

Practical Recommendations

  • For patients with limited financial resources and good manual dexterity or trained caregivers, traditional injectable glucagon powder remains the most cost-effective option 1

  • For patients or caregivers concerned about ease of use during emergencies, the slightly higher cost of nasal glucagon (Baqsimi) at $270 NADAC may be justified by its simpler administration 5, 6, 7

  • All glucagon products should be stored according to specific product instructions and replaced when they reach their expiration date to ensure safe and effective use 1

  • Patients should be educated on proper storage and use of their chosen glucagon product, and caregivers should be trained on administration techniques 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cost-Effectiveness of DPP-4 Inhibitors for Medicare Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Nasal glucagon - a new way to treat severe hypoglycemia in patients with diabetes.

Pediatric endocrinology, diabetes, and metabolism, 2020

Research

Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies.

Diabetes, metabolic syndrome and obesity : targets and therapy, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.